Legal Representation
Attorney
Joshua G. Gigger
USPTO Deadlines
Next Deadline
40 days remaining
NOA E-Mailed - SOU Required
Due Date
February 04, 2026
Extension Available
Until August 04, 2026
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 19, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 18, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 18, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 18, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 4, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 10, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 10, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 4, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 18, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 13, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 13, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 13, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 7, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 7, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 7, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 7, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 2, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 26, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for use in oncology; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of prostate cancer; androgen biosynthesis inhibitors in the nature of pharmaceutical preparations for use in oncology; androgen biosynthesis inhibitors in the nature of pharmaceutical preparations for the treatment of cancer; androgen biosynthesis inhibitors in the nature of pharmaceutical preparations for the treatment of prostate cancer; pharmaceutical products affecting hormone levels for medical purposes, specifically for the treatment of cancer
Classification
International Classes
005